Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?

Leuk Res. 2003 May;27(5):465-6. doi: 10.1016/s0145-2126(02)00225-4.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / therapeutic use
  • Case Management*
  • Chlorambucil / therapeutic use
  • Cladribine / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Humans
  • Immunoglobulin M / blood
  • Male
  • Middle Aged
  • Mitoxantrone / therapeutic use
  • Plasmapheresis
  • Prednisone / therapeutic use
  • Rituximab
  • Severity of Illness Index
  • Thalidomide / therapeutic use
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use
  • Vinblastine / analogs & derivatives*
  • Vinblastine / therapeutic use
  • Vincristine / therapeutic use
  • Vinorelbine
  • Waldenstrom Macroglobulinemia / drug therapy
  • Waldenstrom Macroglobulinemia / therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunoglobulin M
  • Bleomycin
  • Chlorambucil
  • Cladribine
  • Rituximab
  • Thalidomide
  • Vincristine
  • Vinblastine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Mitoxantrone
  • Vidarabine
  • fludarabine
  • Vinorelbine
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • VNCOP-B protocol